MX2019009119A - Conjugados de farmacos y anticuerpos anti-ccr7. - Google Patents
Conjugados de farmacos y anticuerpos anti-ccr7.Info
- Publication number
- MX2019009119A MX2019009119A MX2019009119A MX2019009119A MX2019009119A MX 2019009119 A MX2019009119 A MX 2019009119A MX 2019009119 A MX2019009119 A MX 2019009119A MX 2019009119 A MX2019009119 A MX 2019009119A MX 2019009119 A MX2019009119 A MX 2019009119A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugates
- antibody drug
- antibodies
- antigen binding
- binding fragments
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta solicitud describe anticuerpos anti-CCR7, sus fragmentos de unión a antígeno y conjugados de fármaco y anticuerpo de dichos anticuerpos o fragmentos de unión a antígeno. La invención también se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, los fragmentos de unión a antígeno y los conjugados de fármaco y anticuerpo. En el presente documento también se describen métodos para producir los anticuerpos, los fragmentos de unión a antígeno y los conjugados de fármaco y anticuerpo, y métodos para usar los anticuerpos y los fragmentos de unión a antígeno como reactivos de diagnóstico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762454476P | 2017-02-03 | 2017-02-03 | |
PCT/IB2018/050639 WO2018142322A1 (en) | 2017-02-03 | 2018-02-01 | Anti-ccr7 antibody drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019009119A true MX2019009119A (es) | 2019-11-21 |
Family
ID=61283268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009119A MX2019009119A (es) | 2017-02-03 | 2018-02-01 | Conjugados de farmacos y anticuerpos anti-ccr7. |
MX2022011732A MX2022011732A (es) | 2017-02-03 | 2019-07-31 | Conjugados de farmacos y anticuerpos anti-ccr7. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011732A MX2022011732A (es) | 2017-02-03 | 2019-07-31 | Conjugados de farmacos y anticuerpos anti-ccr7. |
Country Status (25)
Country | Link |
---|---|
US (2) | US11634497B2 (es) |
EP (1) | EP3577139A1 (es) |
JP (1) | JP7312111B2 (es) |
CN (1) | CN110248963B (es) |
AR (1) | AR110920A1 (es) |
AU (1) | AU2018215701B2 (es) |
BR (1) | BR112019015950A2 (es) |
CA (1) | CA3049639A1 (es) |
CL (1) | CL2019002144A1 (es) |
CO (1) | CO2019008209A2 (es) |
CR (1) | CR20190346A (es) |
CU (1) | CU24648B1 (es) |
EA (1) | EA201991763A1 (es) |
EC (1) | ECSP19054235A (es) |
IL (1) | IL267834B2 (es) |
JO (1) | JOP20190187A1 (es) |
MA (1) | MA51778A (es) |
MX (2) | MX2019009119A (es) |
MY (1) | MY194997A (es) |
PE (1) | PE20191328A1 (es) |
PH (1) | PH12019501773A1 (es) |
SG (1) | SG11201906229QA (es) |
TW (1) | TW202323292A (es) |
UY (1) | UY37591A (es) |
WO (1) | WO2018142322A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
NZ756323A (en) | 2017-02-28 | 2022-07-01 | Seagen Inc | Cysteine mutated antibodies for conjugation |
EP3898693A4 (en) | 2018-12-21 | 2022-09-21 | Avidity Biosciences, Inc. | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF |
AU2020361461A1 (en) * | 2019-10-09 | 2022-04-21 | Catapult Therapeutics B.V. | Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or Bcl2- inhibitor for treating hematological malignancies |
WO2021078219A1 (en) * | 2019-10-25 | 2021-04-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-cd47 antibodies and uses thereof |
IL310900A (en) | 2020-03-19 | 2024-04-01 | Avidity Biosciences Inc | Preparations and methods for the treatment of facial, back and arm muscle atrophy |
WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
US20230181756A1 (en) * | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
US20230405138A1 (en) | 2020-07-27 | 2023-12-21 | Tuojie Biotech (Shanghai) Co., Ltd. | Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof |
US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
AU2022267219A1 (en) * | 2021-04-26 | 2023-10-05 | Memorial Hospital For Cancer And Allied Diseases | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
KR20230161759A (ko) * | 2022-05-19 | 2023-11-28 | 국민대학교산학협력단 | Ccr7의 활성 조절 항체 |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
DK0563475T3 (da) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Konjugater af cellebindende midler og derivater af CC-1065 |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2128208C (en) | 1992-11-17 | 2004-01-06 | Ronald Godiska | Novel seven transmembrane receptors |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
DE69630514D1 (de) | 1995-01-05 | 2003-12-04 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
PT885002E (pt) | 1996-03-04 | 2011-07-14 | Massachusetts Inst Technology | Materiais e métodos para aumento da internalização celular |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
JP3884484B2 (ja) | 1997-01-16 | 2007-02-21 | マサチューセッツ インスティチュート オブ テクノロジー | 吸入用粒子の調製 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6043551A (en) | 1997-09-30 | 2000-03-28 | Intel Corporation | Metal locking structures to prevent a passivation layer from delaminating |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US6153441A (en) | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69907456T2 (de) | 1998-06-24 | 2004-03-25 | Advanced Inhalation Research, Inc., Cambridge | Grosse poröse partikel ausgestossen von einem inhalator |
ATE347378T1 (de) | 1998-07-22 | 2006-12-15 | Osprey Pharmaceuticals Ltd | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
AU5459599A (en) | 1998-08-17 | 2000-03-06 | Schering Corporation | Regulation of dendritic cell trafficking |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
CA2389979C (en) | 1999-11-24 | 2011-08-16 | Schering Corporation | Methods of inhibiting metastasis |
AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
WO2002010138A2 (en) | 2000-08-01 | 2002-02-07 | Schering Corporation | Uses of mammalian genes and related reagents |
US6411163B1 (en) | 2000-08-14 | 2002-06-25 | Intersil Americas Inc. | Transconductance amplifier circuit |
WO2002062850A2 (en) | 2001-02-02 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
CA2439279A1 (en) | 2001-02-28 | 2002-09-06 | Protein Design Labs, Inc. | Chemokine receptors and disease |
US20020168358A1 (en) | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
DK1417488T3 (da) | 2001-06-07 | 2007-03-05 | Chemocentryx Inc | Cellemigrasionsassay |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
ATE415413T1 (de) | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2004104574A2 (en) | 2003-05-23 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7) |
ITRM20030386A1 (it) | 2003-08-05 | 2005-02-06 | Istituto Naz Per Le Malattie Infettive Lazz | Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici. |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
BRPI0506883A (pt) | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
AR048927A1 (es) | 2004-04-07 | 2006-06-14 | Novartis Ag | Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa |
US7274964B2 (en) | 2004-04-16 | 2007-09-25 | Bal Seal Engineering Co., Inc. | Use of an axial canted coil spring as an electrical contact to minimize resistivity variations under dynamic loads |
CA2570321C (en) | 2004-07-02 | 2013-10-08 | Genentech, Inc. | Inhibitors of iap |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
WO2006056061A1 (en) | 2004-11-24 | 2006-06-01 | Val-Chum, S.E.C. | Methods to identify, prepare, and use naive t cell recent thymic emigrants |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
ES2503719T3 (es) | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
CA2601243A1 (en) | 2005-03-09 | 2006-09-21 | Board Of Regents, The University Of Texas System | Methods and composition related to in vivo imaging of gene expression |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
WO2007005605A2 (en) | 2005-07-01 | 2007-01-11 | Washington University In St. Louis | Phosphospecific chemokine receptor antibodies |
WO2007003216A1 (en) * | 2005-07-06 | 2007-01-11 | Universidad Autónoma de Madrid | Anti-ccr7 receptor antibodies for the treatment of cancer |
PL1928503T3 (pl) | 2005-08-24 | 2012-12-31 | Immunogen Inc | Sposób wytwarzania koniugatów majtazynoid-przeciwciało |
JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | 毒素とコンジュゲートしたeph受容体抗体 |
EP1937311A2 (en) | 2005-09-30 | 2008-07-02 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for modulating immune tolerance |
WO2007048022A2 (en) | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
WO2007055823A2 (en) | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Gpcr expressing cell lines and antibodies |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
BRPI0711237A2 (pt) | 2006-05-23 | 2011-08-23 | Vb Medicare Pvt Ltd | processo de purificação e recuperação de uma amida terciária a partir de uma composição lìquida aquosa |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
CA2673668A1 (en) | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
JP5368428B2 (ja) | 2007-04-30 | 2013-12-18 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
EP2073009A1 (en) | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR20210005318A (ko) | 2008-04-30 | 2021-01-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
WO2009139853A2 (en) | 2008-05-14 | 2009-11-19 | Kim, Eldar | Human monoclonal antibodies against human chemokine receptor ccr7 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
SG176068A1 (en) | 2009-06-03 | 2011-12-29 | Immunogen Inc | Conjugation methods |
BRPI1015234A2 (pt) | 2009-06-22 | 2018-02-20 | Medimmune Llc | regiões fc projetadas para conjugação sítio específica. |
EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
US8276780B2 (en) | 2009-11-18 | 2012-10-02 | Snyder Industries, Inc. | Fitting torque arm restraint |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011123903A1 (en) | 2010-04-08 | 2011-10-13 | Adelaide Research & Innovation Pty Ltd | Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof |
CA2813203C (en) | 2010-09-28 | 2022-10-18 | Sekisui Chemical Co., Ltd. | Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier |
US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
US9670277B2 (en) | 2011-02-24 | 2017-06-06 | The Schepens Eye Reasearch Institute, Inc. | Compositions and methods for treating inflammatory conditions of the ocular surface |
MX2013011201A (es) | 2011-03-29 | 2013-12-16 | Immunogen Inc | Proceso para la elaboracion de conjugados de mejor homogeneidad. |
RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
EP3693041A1 (en) | 2011-06-13 | 2020-08-12 | TLA Targeted Immunotherapies AB | Treating cancer |
EP3176583B1 (en) | 2011-06-13 | 2019-09-11 | TLA Targeted Immunotherapies AB | Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome |
WO2012172346A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating respiratory conditions |
RU2011130448A (ru) | 2011-07-22 | 2013-01-27 | Зао "Евроген" | Методы и наборы для увеличения разнообразия т-клеток |
SG190466A1 (en) | 2011-11-18 | 2013-06-28 | Agency Science Tech & Res | Methods for diagnosis and/or prognosis of ovarian cancer |
EP2814525A1 (en) | 2012-02-13 | 2014-12-24 | Cook Medical Technologies LLC | Medical devices for collecting pathogenic cells |
WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
BR112014030098A2 (pt) | 2012-06-04 | 2017-07-25 | Irm Llc | métodos de rotulagem específica de sítio e moléculas produzidas pelos mesmos |
WO2013184200A1 (en) | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
US20150307619A1 (en) | 2012-12-13 | 2015-10-29 | The Schepens Eye Research Institute, Inc. | Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors |
PT2953976T (pt) | 2013-02-08 | 2021-06-23 | Novartis Ag | Sítios específicos de modificação de anticorpos para preparar imunoconjugados |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
EP3566750A3 (en) * | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2970985A1 (en) | 2013-03-14 | 2016-01-20 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
EP2970483A2 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
US10132309B2 (en) | 2013-03-15 | 2018-11-20 | Integrated Designs, L.P. | Apparatus and method for the remote monitoring, viewing and control of a semiconductor process tool |
ES2871418T3 (es) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Composiciones y métodos de conjugación de anticuerpos específicos de sitio |
WO2015033137A1 (en) | 2013-09-04 | 2015-03-12 | Imperial Innovations Limited | Biological methods and materials for use therein |
GB201315748D0 (en) | 2013-09-04 | 2013-10-16 | Imp Innovations Ltd | Biological methods and materials for use therein |
GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
EA201691251A1 (ru) | 2013-12-17 | 2016-11-30 | Новартис Аг | Цитотоксические пептиды и их конъюгаты |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JP2017509337A (ja) | 2014-03-12 | 2017-04-06 | ノバルティス アーゲー | イムノコンジュゲートを作製する抗体を修飾するための特定部位 |
EP3131558B1 (en) | 2014-04-16 | 2018-11-14 | Genovie AB | Regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract |
US10407743B2 (en) * | 2014-05-22 | 2019-09-10 | Synthon Biopharmaceuticals B.V. | Site-specific conjugation of linker drugs to antibodies and resulting ADCs |
WO2015189791A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
JP6831783B2 (ja) | 2014-11-14 | 2021-02-17 | ノバルティス アーゲー | 抗体薬物コンジュゲート |
EP3234307B1 (en) * | 2014-12-17 | 2019-11-20 | National Oilwell DHT, L.P. | Method of pressure testing a wellbore |
WO2016179472A2 (en) | 2015-05-07 | 2016-11-10 | University Of Maryland, Baltimore | Modulation of natural killer cell tolerance |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
US10893342B2 (en) * | 2016-02-01 | 2021-01-12 | Telefonaktiebolaget Lm Ericsson (Publ) | Reconfigurable optical modulator |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
-
2017
- 2017-06-16 JO JOP/2019/0187A patent/JOP20190187A1/ar unknown
-
2018
- 2018-02-01 TW TW111137885A patent/TW202323292A/zh unknown
- 2018-02-01 AU AU2018215701A patent/AU2018215701B2/en active Active
- 2018-02-01 AR ARP180100236A patent/AR110920A1/es unknown
- 2018-02-01 PE PE2019001507A patent/PE20191328A1/es unknown
- 2018-02-01 US US16/482,173 patent/US11634497B2/en active Active
- 2018-02-01 SG SG11201906229QA patent/SG11201906229QA/en unknown
- 2018-02-01 EA EA201991763A patent/EA201991763A1/ru unknown
- 2018-02-01 MA MA051778A patent/MA51778A/fr unknown
- 2018-02-01 MX MX2019009119A patent/MX2019009119A/es unknown
- 2018-02-01 CN CN201880009163.2A patent/CN110248963B/zh active Active
- 2018-02-01 MY MYPI2019003816A patent/MY194997A/en unknown
- 2018-02-01 BR BR112019015950A patent/BR112019015950A2/pt unknown
- 2018-02-01 CA CA3049639A patent/CA3049639A1/en active Pending
- 2018-02-01 IL IL267834A patent/IL267834B2/en unknown
- 2018-02-01 EP EP18707417.4A patent/EP3577139A1/en active Pending
- 2018-02-01 CR CR20190346A patent/CR20190346A/es unknown
- 2018-02-01 WO PCT/IB2018/050639 patent/WO2018142322A1/en unknown
- 2018-02-01 UY UY0001037591A patent/UY37591A/es unknown
- 2018-02-01 CU CU2019000072A patent/CU24648B1/es unknown
- 2018-02-01 JP JP2019541414A patent/JP7312111B2/ja active Active
-
2019
- 2019-07-29 EC ECSENADI201954235A patent/ECSP19054235A/es unknown
- 2019-07-29 CO CONC2019/0008209A patent/CO2019008209A2/es unknown
- 2019-07-30 CL CL2019002144A patent/CL2019002144A1/es unknown
- 2019-07-30 PH PH12019501773A patent/PH12019501773A1/en unknown
- 2019-07-31 MX MX2022011732A patent/MX2022011732A/es unknown
-
2023
- 2023-02-03 US US18/164,519 patent/US20240092918A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011732A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
PH12017500890A1 (en) | Antibody drug conjugates | |
PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
WO2018031490A3 (en) | Anti-ox40 binding proteins | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
MX2022015197A (es) | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. | |
WO2018069871A3 (en) | Anti-kras binding proteins | |
PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
MX2021007593A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
AU2018345715A8 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra |